The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on October 13, 2021. This approval specifically relates to an efficacy update, signifying an expansion of the drug's approved uses based on new clinical evidence.
Background
Pembrolizumab (Keytruda) is a well-known immunotherapy. Supplemental applications for efficacy typically involve new clinical data supporting an additional indication, a new patient population, or a revised dosing regimen that demonstrates improved outcomes. This particular approval indicates that the FDA has evaluated new evidence confirming the drug's effectiveness in a new or expanded therapeutic context.
What this means
This supplemental efficacy approval for Keytruda (pembrolizumab) provides clinicians with expanded treatment options. It confirms that the FDA has reviewed and accepted new data demonstrating the drug's effectiveness for an additional or modified indication. This allows for its use in a broader patient population or clinical setting, potentially impacting treatment guidelines and patient access to this immunotherapy.
Source
The information regarding this approval was obtained from the U.S. Food and Drug Administration (FDA) website. It is documented under Biologics License Application (BLA) 125514, supplemental application S-122, with the event date of October 13, 2021, and is accessible via accessdata.fda.gov.